asthma is not known, but 82-adrenergic receptors (E2AR) are known to downregulate overnight in nocturnal asthmatics but not normal subjects or nonnocturnal asthmatics. We have recently delineated three polymorphic loci within the coding block of the 82AR which alter amino acids at positions 16, 27 , and 164 and impart specific biochemical and pharmacologic phenotypes to the receptor. In site-directed mutagenesis/recombinant expression studies we have found that glycine at position 16 (Glyl6) imparts an accelerated agonist-promoted downregulation of E2AR as compared to arginine at this position (Arg16). We hypothesized that Gly16 might be overrepresented in nocturnal asthmatics and thus determined the ft2AR genotypes of two welldefined asthmatic cohorts: 23 nocturnal asthmatics with 34±2% nocturnal depression of peak expiratory flow rates, and 22 nonnocturnal asthmatics with virtually no such depression (2.3+0.8%). The frequency of the Glyl6 allele was 80.4% in the nocturnal group as compared to 52.2% in the nonnocturnal group, while the Arg16 allele was present in 19.6 and 47.8%, respectively. This overrepresentation of the Glyl6 allele in nocturnal asthma was significant at P = 0.007 with an odds ratio of having nocturnal asthma and the Glyl6 polymorphism being 3.8. Comparisons of the two cohorts as to homozygosity for Glyl6, homozygosity for Argl6, or heterozygosity were also consistent with segregation of Glyl6 with nocturnal asthma. There was no difference in the frequency of polymorphisms at loci 27 (Gln27 or Glu27) and 164 (Thrl64 or 11e164) between the two groups.
Thus the Gly16 polymorphism of the fi2AR, which imparts an enhanced downregulation of receptor number, is overrepresented in nocturnal asthma and appears to be an important genetic factor in the expression of this asthmatic phenotype. (J. Clin. Invest. 1995. 95:1635-1641.) Key
Introduction
Patients with nocturnal asthma represent a subset of asthmatics who experience a marked worsening of airway obstruction and symptoms while asleep (1, 2) . Typically, in these patients symptoms and airway obstruction are worse in the early morning hours. In addition to increased airway resistance and decreased peak expiratory flow rate, nocturnal asthmatics display greater bronchial hyperreactivity as compared to nonnocturnal asthmatics during this time (3, 4) . While the pathophysiologic basis for nocturnal asthma is not clear, several studies have suggested that autonomic function may be different in nocturnal asthma as compared to nonnocturnal asthma (5) (6) (7) (8) . Particularly germane to the current study, we have shown in a previous study that circulating neutrophil and lymphocyte 62-adrenergic receptors (/62AR),' which are potential markers for /32ARs of bronchial smooth muscle and other lung cells, decrease at 4:00 a.m. compared to 4:00 p.m. in patients with nocturnal asthma (7) . No such downregulation of 62AR was found in nonnocturnal asthmatics or normal subjects. The mechanism responsible for this nocturnal /2AR downregulation in nocturnal asthma is not known, but given the role of /32AR in modulating bronchial smooth muscle relaxation and other potentially important functions in asthma, such downregulation may be an important event in the development of nocturnal asthma.
Recently, we have found that there is heterogeneity in the structure of the ,62AR in the human population (9) . Six different polymorphic forms of the 62AR have been identified. These polymorphisms consist of amino acid substitutions at the positions indicated in Table I . We have mimicked these polymorphisms by site-directed mutagenesis of the cloned human /62AR cDNA, expressed them in Chinese hamster fibroblasts, and found that some of these 62ARs indeed display different pharmacologic properties (10, 11) . Of particular interest in regard to asthma, the presence of glycine at position 16 of the 32AR imparts enhanced agonist-promoted downregulation ( 11 The allele-specific PCR technique was verified by direct dideoxy sequencing of PCR products generated using sequencing primers different from those used in the PCR. In addition, plasmids consisting of wildtype f32AR cDNA or mutated cDNA corresponding to the above polymorphisms were used as positive and negative control templates for the allele-specific PCR studies. Methods used to develop these constructs were as previously described (10, 11 (15) . Physiologic variables are shown by the mean+SE and were compared using the Mann-Whitney U test, with a P value of < 0.05 considered significant.
Results
Asthmatic cohorts. (Table II) and the between group difference was significant (P = 0.004). Allele-specific PCR. Fig. 1 illustrates the specificity of the allele-specific PCR for delineating polymorphisms at nucleic acid 46 (corresponding to amino acid 16). As shown in Fig. 1 A, when reactions were carried out using plasmids containing 32AR sequences encoding for Argl6 or Glyl6 as templates, PCR products resulted only when the 3' nucleotide of the primers matched with that of the template sequence. When both plasmids were present (mimicking the heterozygous state) products were obtained with both primers. Fig. 1 B shows the results of allele-specific PCR from three patients who were either homozygous for Argl6, homozygous for Glyl6, or heterozygous at this locus. Dideoxy sequencing, shown in Fig. 1 C, confirms the presence of the different polymorphisms at this site. Primer pairs designed for the identification of polymorphisms at nucleic acids 79 and 491 (amino acids 27 and 164) were also tested in the same manner as that described above, and each was capable of specifically detecting the intended polymorphism (data not shown).
/32AR genotypes ofnocturnal and nonnocturnal asthmatics.
Allele-specific PCR was performed on the 45 patients from the two cohorts to delineate polymorphisms at amino acids 16, 27, and 164. The results, as shown in Tables HI and IV, can 
Discussion
Nocturnal worsening of airway obstruction in asthmatics is a well-documented phenomenon. Turner-Warwick in a large population study found that 39% of outpatient asthmatics had subjective nightly worsening of symptoms (17) . The importance of this nighttime worsening stems from the fact that in addition to sleep disturbances, 70% of deaths due to asthma occur during sleep-related hours (18) . Also, -80% of respiratory arrests due to asthma occur during the same period, with the single most important risk factor for such crises being diurnal variation in PEFR (19) . The pathophysiologic mechanism of nocturnal asthma is not clear but such factors as hormonal circadian rhythms (5, 6, 8, 20) , nocturnal worsening of inflammation (8, 21) , and autonomic nervous system dysfunction (5-8) have been implicated in previous studies. Decreases in endogenous cortisol, which may result in increased inflammation and decreased ,62AR expression, have been the subject of several investigations (7, 8, 20, 22) . A circadian decrease in plasma cortisol levels (with the nadir being around midnight) is observed in normal subjects (20). An exaggerated decrease in plasma cortisol has been reported in patients with nocturnal asthma (20, 22) . Others, however, report no such differences between normal subjects, nocturnal asthmatics, and/or nonnocturnal asthmatics (7, 8) . Differences in plasma histamine have also been reported (6), but again this is not a universal finding (8) . An increased vagal activity, which promotes bronchoconstriction, has also been observed in nocturnal asthma (5) . Diurnal variations in plasma catecholamine levels have been examined by a number of investigators with variable findings. Some have reported no differences in catecholamine levels or their diurnal variation between asthmatics with nocturnal worsening of PEFR and either nonnocturnal asthmatics or normal subjects (7, 20) . Others have shown differences in epinephrine or norepinephrine levels between nocturnal and nonnocturnal asthmatics, and correlations between pulmonary function and fluctuations in plasma epinephrine (5, 6, 8 (9) (10) (11) 23) . However, even with the limited number of normal subjects that we have studied (9) , it is clear that some of these polymorphisms are found frequently in the normal population and thus wild-type needs to be carefully defined. The most appropriate reference to these polymorphisms thus appears to be as we have used in the current work, i.e., Argl6, Glyl6, etc. To further explore the functional relevance of these polymorphisms, we mimicked these by site-directed mutagenesis of the wild-type /2AR cDNA and expressed these in Chinese ham-/32-Adrenergic Receptor Polymorphisms in Asthmaster fibroblasts which normally do not express /32AR. We found that the substitution of Ile for Thr at amino acid position 164 resulted in an -3-fold decrease in agonist binding affinity and -50% depression of agonist and nonagonist dependent coupling to adenylyl cyclase (10) . In our recombinant expression system, substitution of Gly for Arg at position 16, Glu for Gln at position 27, or the combination of both, did not affect agonist or antagonist binding, sequestration, or coupling, but in contrast imparted altered agonist-promoted downregulation of the receptor ( 11 ) . Glu at position 27 with Arg in position 16 resulted in a receptor that was virtually refractory to long-term (24 h) agonist-promoted downregulation of receptor number. On the other hand, the presence of Gly at position 16, regardless of whether a Glu or Gln is present at position 27, results in a more profound degree of long-term agonist-promoted downregulation as compared to Argl6 (11) . In these latter studies, however, we did not assess the relative functional consequences of differences in these degrees of downregulation. The mechanisms of how these amino-terminal polymorphisms impart different agonist-promoted regulation are not fully known, but an altered degradation process of these receptor proteins appears to be the primary mechanism associated with these two genotypes (11) . The rare (-' 1%) polymorphism at position 34 (substitution of Met for Val) confers no detectable alterations in receptor binding, coupling, or regulation (Green S. A., and S. B. Liggett, unpublished results).
Given our previous observation regarding the downregulation of /32AR at 4:00 a.m. in nocturnal asthmatics (7), and the above findings of altered downregulation imparted by some /32AR polymorphisms, we were prompted to examine the /2AR genotype in two groups of asthmatics who did or did not have nocturnal asthma. We found a significant overrepresentation of the Glyl6 polymorphism in the nocturnal asthmatic group. On the other hand, the frequency of the polymorphism at amino acid 27 was not different between the two groups. The polymorphism at position 164 was too infrequent to be considered (Table III). The Glyl6 polymorphism is indeed the one that exhibits enhanced downregulation in recombinant studies (11) . Our findings thus suggest that a contributing factor to the pathophysiology of nocturnal asthma is the presence of the Glyl6 f32AR polymorphism.
The assignment of asthmatics to the nocturnal vs nonnocturnal group was based on the overnight fall in PEFR, which was 34.0+2.0% in the nocturnal group and 2.3+0.8% in the nonnocturnal group. Daytime pulmonary function trended towards being worse in the nocturnal group as compared to the nonnocturnal group (Table II) . Consistent with this is the observed greater use of theophylline and inhaled corticosteroids in the nocturnal group. Importantly, the use of /3-agonists was the same in both groups. We do not f32AR are localized in a number of regions of the lung which may be involved in the pathophysiology of asthma (reviewed in [25] [26] [27] . Clearly the most well-characterized of these is bronchial smooth muscle, where activation of 32AR results in relaxation and increased airway diameter. While such bronchodilatation is the primary therapeutic goal for administering /8-agonists, the role of the 632AR in the absence of exogenous agonist in modulating airway tone is not clear. Relevant to asthma, ,62AR are also present on epithelial cells, submucosal glands, and vascular smooth muscle. In addition, these receptors are expressed on a number of immune cells such as lymphocytes, neutrophils, and macrophages. From many studies in humans, it is clear that /32AR expression and function is dynamically regulated by a number of factors (28) . The stimulus for induction of downregulation of the Glyl6 polymorphic form of the /62AR in nocturnal asthmatics is not clear. Both nocturnal and nonnocturnal asthmatics have been reported to have peak plasma catecholamine levels in the late afternoon to early evening (6, 8) . Given the typical time course required for ,62AR downregulation, such a peak in endogenous agonist may be sufficient to induce downregulation of the more sensitive Glyl6 polymorphism in nocturnal asthmatics. Cortisol also regulates expression of /2AR and undergoes a diurnal variation (20).
We do not know, however, whether the Glyl6 polymorphism is regulated differently by corticosteroids at this time.
It is important to note that the Glyl6 polymorphism of the ,62AR appears from our study to be associated with one particular phenotype of asthma. It is clear from several studies that asthma and/or atopy may be the result of multiple gene defects. Atopy or elevated IgE levels have been reported to segregate with chromosome 11q13 (29) , with a specific polymorphism of the IgE receptor (30) , with a region near the IL-4 locus on chromosome 5q31.1 (31) , and another region (the D5S436 marker) on chromosome 5 (32) . It is intruiging to note that one of the few known genes near this latter marker is the ,62AR.
Further studies saturating this region with additional markers will be necessary to determine the region of greatest segregation. Given the above results coupled with our current report, the involvement of f32AR polymorphisms in a multigene defect scenario for asthma or certain asthmatic phenotypes appears reasonable.
In conclusion, we have found an association between the presence of nocturnal asthma and a polymorphism (Glyl6) of the /2AR. In recombinant studies, this polymorphism imparts enhanced downregulation of the receptor, which is consistent with the nocturnal downregulation of 82AR and the depressed response to (3-agonists observed in nocturnal asthma. While there are clearly other processes that also participate in nocturnal asthma pathophysiology, the correlation of the results of genetic, physiologic, and pharmacologic studies are consistent with the Argl6 /32AR polymorphism being an important factor in this subset of asthmatics.
